it is a highly selective Src kinase inhibitor that has demonstrated efficacy in pre-clinical animal models of colon, pancreatic, prostate and breast cancer. It is a substrate-targeted kinase inhibitor. it, belongs to an emerging new family of targeted cancer treatments called protein kinase inhibitors. 
